Igentify Spółka z Ograniczoną Odpowiedzialnością (KRS 0001231907, NIP 5273211997) is a Polish company, headquartered in Warszawa, Mazowieckie voivodeship. IGENTIFY operates in: Scientific research and development (PKD 72.10.Z). Industry: Research and development. The company has been listed in the National Court Register since March 24, 2026.
No arrears identified in the analyzed sources
No arrears or bankruptcy proceedings identified in the analyzed sources.
Business profile - Igentify
Identity
- Name
- Igentify Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
- Founded
- March 24, 2026
- Registry status as of
- June 15, 2026
- Latest entry
- June 15, 2026
- Founding act
- 23.03.2026
Articles of association history (1)
- March 23, 2026: 23.03.2026
Activities
Main activity
72.10.ZScientific research and development
Address and contact
- Address
- UL. WOLSKA, 58, 1, 04-426, WARSZAWA, POLSKA
- Voivodeship
- MAZOWIECKIE
- District
- WARSZAWA
- BOZENA.HOFFMANN@GMAIL.COM
- Website
- Not disclosed in the registry
- E-delivery address
- AE:PL-35278-86321-IFBRG-16
Operational status - Igentify
Founded
March 24, 2026
0 years in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
WARSZAWA
MAZOWIECKIE
Primary PKD
72.10.Z
Scientific research and development
Share capital
5.0 K PLN
50 shares total
Shareholders
1
shareholder
Board
1 person
Filed years
N/A
Registry entries
4
latest: June 15, 2026
No KPI data - financial statements and valuation are unavailable for this company.
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - Igentify.
No ratings
Related articles
News
Bioceltix in the final EMA dialogue phase: BCX-CM-J could become Europe's first veterinary cell-therapy drug for dogs
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase regarding BCX-CM-J - Europe's first veterinary cell-therapy drug from mesenchymal stem cells for dogs with osteoarthritis. Responses to the final EMA questions are due in May 2026; the CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. Pre-commercial biotech: 2024 closed with a PLN 14.9 m loss on zero revenue; cash of PLN 33.6 m at year-end. Trigon DM maintained a buy rating with a price target of PLN 127.2.
News
Captor Therapeutics: PLN 36 m of cash at 30 September 2025, runway to mid-2026 - clinical data versus the cash clock
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) - a pre-commercial biotech specialising in TPD (Targeted Protein Degradation) - closed Q3 2025 with PLN 36 m of cash and grants securing financing to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I - the first patient dosed at Barcelona Clinic Liver Cancer. CT-03 (MCL-1 degrader) nearing clinical entry. Without a new R&D partnership or equity issuance in 2026, the company will need additional financing.
